ArticleIranian journal of public health2023
Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors.
Article in Iranian journal of public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the most convenient and commonly used for clinical diagnosis, cancer biomarker has been widely used in the auxiliary diagnosis of tumors, the observation of curative effect, the judgment of prognosis, and the monitoring of the disease. Methods: Pan-cancer analysis was used to validate the value of Dehydrogenase/Reductase 2 (DHRS2) as a tumor prognostic marker in various tumors. The relationship of DHRS2 to TMB and MSI was used to explain the effect of DHRS2 on genomic instability. Online cbioportal was used to analyze DHRS2 mutations in tumors. Finally, 33 clinical tumor samples were collected in 2021 who were enrolled into the Affiliated Lianyun-gang Oriental Hospital of Xuzhou Medical University, to verify the expression and diagnostic prognostic value of DHRS2. Results: The expression of DHRS2 was up-regulated in a variety of tumors and had adverse effects on the overall survival, disease-free interval, and progression-free interval of tumor patients. DHRS2 was associated with tumor genome instability, confirming that DHRS2 was correlated with tumorigenesis. In addition, DHRS2 had different mutation sites in various tumors. DHRS2 was up-regulated and was a poor prognosis biomarker in clinical tumor samples. Conclusion: DHRS2 was aberrantly expressed in tumors and has diagnostic prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.